BONDUELLE
A French SCA (Partnership Limited by Shares) with a capital of 56,000,000 Euro
Head Office: La Woestyne, 59173 Renescure.
Commercial and Companies Register of Dunkerque B 447 250 044
Villeneuve d'Ascq, the 19th of October 2017
Option for payment of the dividend in shares
and
Statement of availability of the 2016-2017 Registration Document
Bonduelle proposes the payment of the dividend in shares to its General Shareholders' Meeting on December 7th, 2017
It will be proposed to the Bonduelle SCA's General Shareholders' Meeting to be held on December 7th, 2017, that an ordinary dividend of 0.45 euro per share be paid with respect to fiscal year 2016-2017.
In order to reward the loyalty of its shareholders and on proposal of the Supervisory Board, Pierre & Benoît Bonduelle SAS, acting as General Partner and General Manager of Bonduelle SCA, and represented by its President, Mr. Christophe Bonduelle, made the decision to offer to each shareholder an option for the dividend to be paid in cash and/or in shares for all or part of the said dividend. The issued price of the share received as dividend will be equal to 90% of the average of the opening trading prices on the twenty stock exchange trading days preceding the date of the General Shareholders' Meeting.
Subject to the approval by the General Shareholders' Meeting, the calendar would be the following:
- December 7th, 2017: Determination of the issue price of Bonduelle new shares for the payment of dividend in shares
- December 12th, 2017: Record date (last day to acquire shares giving right to dividends)
- December 13th, 2017: Ex dividend date
- December 13th - 27th, 2017 (including said days): Exercise period for the option to have the dividend paid in shares
- January 9th, 2018: Payment date of dividend in cash and/or delivery of the shares.
Statement of availability of the 2016-2017 Registration Document
The company announces that its 2016-2017 Registration Document (Document de Référence) was filed with the Autorité des Marchés Financiers (AMF) on the 18th of October 2017.
This document is available on the company's website www.bonduelle.com (http://www.bonduelle.com/fr/investisseurs.html) and on the AMF website www.amf-france.org. It is also available at the head office: Rue Nicolas Appert - 59653 Villeneuve d'Ascq. A free translation into English will be available on the company's website as from the 27th of October 2017.
The following documents have been integrated into the Registration Document:
- 2016-2017 Annual Financial Report;
- Reporting on internal control and corporate governance;
- The amount of the auditors fees;
- The description of the stock buyback program.
This document is a free translation into English and has no other value than an informative one. Should there be any difference between the French and the English version, only the French-language version shall be deemed authentic and considered as expressing the exact information published by Bonduelle.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e7c6579c-fa09-4b6e-8d3d-18792ecb620a


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 



